An AI technology that makes the world's
medicines faster?

Hyper Lab Blog - Drug Discovery

Discuss drug discovery issues on the Hyper Lab blog.

Most Recent
FDA Approved Drugs in January 2025 – Latest Breakthroughs –.png
Drug Discovery
FDA Approved Drugs in January 2025 – Latest Breakthroughs
In January 2025, the U.S. Food and Drug Administration (FDA) approved several new drugs targeting various diseases.
HITS Hyper Lab TEAM2025.02.06
AI Drug Discovery CASE STUDY - EP1. Hyper Screening.png
Drug Discovery
AI Drug Discovery case study - EP1. Hyper Screening
We introduce a case study on utilizing Hyper Screening to develop a MARK4 inhibitor drug. This article covers the process from identifying initial hit compounds to analyzing experimental results.
Heejin Jung, R&D Strategy Team Lead2025.01.20
drug-discovery-ai-hyperlab
Drug Discovery
AI Drug Discovery with Hyper Lab: “9x Higher Screening Success Rate, 90% Faster Development Time”
AI Drug Discovery: From 5 Years to Just 3 Months—Discovering a 100nM Active Compound with Hyper Lab
Jaechang Lim, CTO2025.01.14
2024 FDA Approved  Drug Roundup.png
Drug Discovery
2024 FDA Approved Drug Roundup
Oncology, immunology, and metabolic diseases dominated the top 50 FDA-approved drugs in 2024, with innovative treatments like Lazertinib and diverse drug types.
Seungmin Jung, R&D Starategy Team Researcher2025.01.06
Cobenfy_ A paradigm shift after 70 years, a new path in schizophrenia treatment.png
Drug Discovery
Cobenfy: Redefining Schizophrenia Treatment After 70 Years
Cobenfy is an FDA-approved oral schizophrenia treatment targeting muscarinic rather than dopamine receptors. Its rapid symptom improvement and fewer side effects hint at a paradigm shift, making upcoming clinical findings highly anticipated.
Seungmin Jung, R&D Starategy Team Researcher2024.12.10
FDA Grants Accelerated Approval for the First Primary Biliary Cholangitis (PBC) Treatment, Seladelpar (1).png
Drug Discovery
FDA Grants Accelerated Approval for the First Primary Biliary Cholangitis (PBC) Treatment, ‘Seladelpar’
Seladelpar, a treatment for Primary Biliary Cholangitis, has received FDA accelerated approval. This rare autoimmune disease, mainly affecting middle-aged women, is now addressed by seladelpar’s high selectivity and fewer side effects.
Heejin Jung, R&D Strategy Team Lead2024.10.18
ddc-2024
Drug Discovery
DDC 2024 Poster Analysis
In this article, we analyze the posters submitted to DDC 2024, categorized by country, organization, and topic.
Jimmy, AI Business Team Researcher 2024.03.14
ai-paper-drug-discovery
Drug Discovery
Study AI drug discovery Start with these 3 papers
We've summarized three important papers for AI drug discovery. These papers will help you understand the fundamentals of AI drug discovery and move forward with the latest research.
Jaechang Lim, Co-founder2024.03.08
binding-site-define
Drug Discovery
How to discover and define binding sites in structure-based drug discovery
We've covered things to consider when defining a binding site during structure-based drug discovery research (SBDD).
Sehan Lee, AI Business Lead2024.03.08
NeurIPS
Drug Discovery
See the future of AI drug discovery at NeurIPS 2023
What did we see at NeurIPS 2023 about the future of drug discovery?
Wooyoun Kim, CEO 2024.03.08